Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients’ lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes. Servier is founded on the principle of serving and governed by an independent non-profit foundation. With this unique operating model, the company can be deliberate about putting patients ahead of profits. In fact, Servier re-invests 25 percent of revenue into research and development each year. Servier is committed to therapeutic progress to serve patient needs and strives to provide future generations with a world where quality healthcare is available and accessible to all. See our community guidelines here: https://www.servier.us/community-guidelines To report a suspected adverse event with a Servier product, please visit: https://www.servier.us/contact-us

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. For more information, visit www.deciphera.com.

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. As an organization, Karyopharm is on a mission to improve lives and defeat cancer. In its role as leaders in XPO1 inhibition, Karyopharm delivers on its mission by creating a focused pipeline that targets multiple high unmet need cancer indications, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).

Radius Health is a global biopharmaceutical company focused on addressing unmet medical needs in the area of bone health. Our team works collaboratively and relentlessly to advance our therapies with the goal of improving the lives of patients, their families, and their caregivers. Radius was founded in 2003 and has locations in Boston, Massachusetts, and Wayne, Pennsylvania. If you think you have the same passion and commitment we have, check out www.radiuspharm.com.

Simoniz USA is headquartered in Bolton, CT with operations predominately in the eastern half of the United States and distributes products both nationally and internationally. The company manufactures a diverse product line covering a broad spectrum of markets including the commercial vehicle washing, professional detailing, retail vehicle appearance, and janitorial/ institutional cleaning. Our floor finishes, disinfectants, waxes, and all-purpose cleaners are widely used in hospitals, nursing homes, food service establishments, manufacturing plants, school systems and the hospitality industry. In new car dealerships, Simoniz offers several different programs such as "GlassCoat"​, MotoTect, and PDRPlus.

Specializing in recombinant and traditional chromogenic and turbidimetric reagent technologies, ACC has been a global leader in endotoxin and (1→3)-ß-D-glucans detection products and services for 50 years. ACC pioneered LAL testing methodology and was the first FDA licensed company to manufacture LAL reagents; ACC has grown to be an internationally recognized leader in endotoxin detection. We are headquartered in Falmouth, MA with facilities in the UK and the Netherlands. With a dedication to quality, ACC is certified to I.S. EN ISO 13485:2016 and ISO 13485:2016. We are FDA inspected and operate DEA Licensed and CLIA-certified laboratories. Our endotoxin detection reagents, instruments and software are used within the Pharmaceutical, Medical-Device, Biotechnology, Compounding Pharmacy and Dialysis industries for quality control, product release and research. ACC operates a Contract Test Services (CTS) Laboratory which has specialized in testing for endotoxin contamination for over 40 years. Our CTS laboratory is GMP compliant, ISO registered and DEA licensed and is capable of handling all controlled drug substances except those included in Schedule 1. All testing services can be performed to FDA, USP, EP and/or JP regulatory guidelines. In addition to routine testing, our CTS Laboratory will customize endotoxin testing, troubleshoot difficult samples, develop and/or transfer LAL test methods, design and produce custom depyrogenation controls for oven validation and perform Low Endotoxin Recovery (LER) studies/protocols. ACC also offers a clinical diagnostics product line and operates a CLIA-certified laboratory specializing in (1→3)-ß-D-glucan analysis to support the early diagnosis of Invasive Fungal Infection (IFI). For more information please visit https://www.linkedin.com/in/fungitell-assay-3269a2154/

Corium is a commercial-stage biopharmaceutical company that is leading the development and commercialization of central nervous system (CNS) healthcare therapies that provide clinicians with important treatment options for patients, their families, and their caregivers. Collaborating with some of the world's largest pharmaceutical and consumer product companies, we have a track record and depth of experience in taking products from concept, through development, to manufacturing and final commercialization.

Amylyx Pharmaceuticals, Inc. is a global company committed to the mission of discovery and development of treatments for relentless and progressing neurodegenerative diseases. We work collaboratively across everything we do, aspiring to help support and create #MoreMoments for the neurodegenerative disease community. Community Guidelines: https://bit.ly/3C1v1wz Please be aware of potential phishing scams imitating Amylyx. All authentic communications from Amylyx will be from the Amylyx.com domain.

Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our flagship azetukalner program represents the most advanced potassium channel modulator in clinical development for multiple indications. Building upon the positive results and compelling data from our Phase 2b “X-TOLE” study in adult patients with focal epilepsy, our Phase 3 epilepsy program includes multiple clinical trials evaluating azetukalner in patients with focal onset seizures and primary generalized tonic-clonic seizures. In 2024, we are planning to initiate a Phase 3 azetukalner program in major depressive disorder, based on topline data from our Phase 2 “X-NOVA” clinical trial. In addition, we are proud of the leading-edge science coming out of our discovery labs, including early-stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.

From discovery to product launch and lifecycle management At VCLS (Voisin Consulting Life Sciences), regulatory science guides Biotechnology, Pharmaceutical and Medtech manufacturers throughout product development and commercialization. Starting early in the process, from discovery to the patient, VCLS assists innovators in designing optimized product development plans and regulatory strategies, combining the health ecosystem with commercial success. With a presence in seven locations across three continents and over 200 employees, VCLS serves a broad range of healthtech developers and their investors. Together, we accompany global stakeholders to expedite HealthTech products from discovery to patient access and beyond by bridging Science to Regulatory and Market Access strategies.